Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction

John M Ketcham,Jacob Haling,Shilpi Khare,Vickie Bowcut,David M Briere,Aaron C Burns,Robin J Gunn,Anthony Ivetac,Jon Kuehler,Svitlana Kulyk,Jade Laguer,J David Lawson,Krystal Moya,Natalie Nguyen,Lisa Rahbaek,Barbara Saechao,Christopher R Smith,Niranjan Sudhakar,Nicole C Thomas,Laura Vegar,Darin Vanderpool,Xiaolun Wang,Larry Yan,Peter Olson,James G Christensen,Matthew A Marx

DOI: https://doi.org/10.1021/acs.jmedchem.2c00741

2022-07-28

Abstract:SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRASG12C protein-protein interaction (PPI) can increase the proportion of GDP-loaded KRASG12C, providing a strong mechanistic rationale for combining inhibitors of the SOS1:KRAS complex with inhibitors like MRTX849 that target GDP-loaded KRASG12C. In this report, we detail the design and discovery of MRTX0902─a potent, selective, brain-penetrant, and orally bioavailable SOS1 binder that disrupts the SOS1:KRASG12C PPI. Oral administration of MRTX0902 in combination with MRTX849 results in a significant increase in antitumor activity relative to that of either single agent, including tumor regressions in a subset of animals in the MIA PaCa-2 tumor mouse xenograft model.